Review of clinical trials of pharmacologic interventions for cancer-related fatigue: Focus on psychostimulants and steroids

Cancer Journal (United States)

Volumn 20, Issue 5, 2014, Pages 319-323

  Yennurajalingam, Sriram ^a   Bruera, Eduardo ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cancer related fatigue; Dexamethasone; Fatigue; Methylphenidate; Pharmacological agents; Psychostimulants

Indexed keywords

ANTIDEPRESSANT AGENT; PSYCHOSTIMULANT AGENT; STEROID; CENTRAL STIMULANT AGENT;

CANCER FATIGUE; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER SURVIVOR; HUMAN; META ANALYSIS; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STEROID THERAPY; TREATMENT OUTCOME; TREATMENT RESPONSE; CLINICAL TRIAL (TOPIC); COMPLICATION; FATIGUE; NEOPLASM;

CENTRAL NERVOUS SYSTEM STIMULANTS; CLINICAL TRIALS AS TOPIC; FATIGUE; HUMANS; NEOPLASMS; STEROIDS; TREATMENT OUTCOME;

EID: 84927672743     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/ppo.0000000000000069     Document Type: Review

References (47)

1. Teunissen SCCM, Wesker W, Kruitwagen C., et al. Symptom prevalence in patients with incurable cancer: a systematic review. J Pain Symptom Manage. 2007; 34:94-104.
2. Berger AM, Abernethy AP, Atkinson A, et al. Cancer-related fatigue. J Natl Compr Cancer Netw. 2010; 8:904-931.
3. Radbruch L, Strasser F, Elsner F., et al. Fatigue in palliative care patients-an EAPC approach. Palliat Med. 2008; 22:13-32.
4. Cella D, Davis K, Breitbart W., et al. Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. J Clin Oncol. 2001; 19:3385-3391.
5. Alexander S, Minton O, Stone PC. Evaluation of screening instruments for cancer-related fatigue syndrome in breast cancer survivors. J Clin Oncol. 2009; 27:1197-1201.
6. Andrykowski MA, Schmidt JE, Salsman J.M., et al. Use of a case definition approach to identify cancer-related fatigue in women undergoing adjuvant therapy for breast cancer. J Clin Oncol. 2005; 23:6613-6622.
7. Piper BF, Cella D. Cancer-related fatigue: definitions and clinical subtypes. J Natl Compr Cancer Netw. 2010; 8:958-966.
8. Curt GA, Breitbart W, Cella D., et al. Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist. 2000; 5:353-360.
9. Lis C, Rodeghier M, Grutsch J., et al. Distribution and determinants of patient satisfaction in oncology with a focus on health related quality of life. BMC Health ServRes. 2009; 9:190.
10. Bower JE, Lamkin DM. Inflammation and cancer-related fatigue: mechanisms, contributing factors, and treatment implications. Brain Behav Immun. 2013; 30(Suppl):S48-S57.
11. Yennurajalingam S, Bruera E. Palliative management of fatigue at the close of life: "it feels like my body is just worn out." JAMA. 2007; 297:295-304.
12. Minton O, Richardson A, Sharpe M., et al. Psychostimulants for the management of cancer-related fatigue: a systematic review and meta-analysis. J Pain Symptom Manage. 2011; 41:761-767.
13. Breitbart W, Alici Y. Psychostimulants for cancer-related fatigue. J Natl Compr Cancer Netw. 2010; 8:933-942.
14. Minton O, Sharpe M, Hotopf M., et al. Drug therapy for the management of cancer-related fatigue. Cochrane Database Syst Rev. 2010.
15. Breitbart W, Alici-Evcimen Y. Update on psychotropic medications for cancer-related fatigue. J Natl Compr Cancer Netw. 2007; 5:1081-1091.
16. Bruera E, Chadwick S, Hanson J., et al. Methylphenidate associated with narcotics for the treatment of cancer pain. Cancer Treat Rep. 1987; 71:67-70.
17. Bruera E, Paterson AH, MacDonald RN. Use of methylphenidate as an adjuvant to narcotic analgesics in patients with advanced cancer. J Pain Symptom Manage. 1989; 4:3-6.
18. Bruera E, Driver L, Barnes E.A., et al. Patient-controlled methylphenidate for the management of fatigue in patients with advanced cancer: a preliminary report. J Clin Oncol. 2003; 21:4439-4443.
19. Bruera E, Valero V, Driver L., et al. Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial. J Clin Oncol. 2006; 24:2073-2078.
20. Bruera E, Yennurajalingam S, Palmer J.L., et al. Methylphenidate and/or a nursing telephone intervention for fatigue in patients with advanced cancer: a randomized, placebo-controlled, phase II trial. J Clin Oncol. 2013; 31:2421-2427.
21. Moraska AR, Sood A, Dakhil S.R., et al. Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group NCCTG-N05C7 Trial. J Clin Oncol. 2010; 28:3673-3679.
22. Escalante CP, Reuben JM, Wang X, et al. A randomized, double-blind, 2-period, placebo-controlled crossover trial of a sustained-release methylphenidate in the treatment of fatigue in cancer patients. Cancer J. 2014; 20:8-14.
23. Kerr CW, Drake J, Milch R.A., et al. Effects of methylphenidate on fatigue and depression: a randomized, double-blind, placebo-controlled trial. J Pain Symptom Manage. 2012; 43:68-77.
24. Spathis A, Fife K, Blackhall F., et al. Modafinil for the treatment of fatigue in lung cancer: results of a placebo-controlled, double-blind, randomized trial. J Clin Oncol. 2014; 32:1882-1888.
25. Blackhall L PG, Shu J., Baum L, et al. A pilot study evaluating the safety and efficacy of modafinil for cancer-related fatigue. J Palliat Med. 2009; 12:433-439.
26. Spathis A, Dhillan R, Booden D., et al. Modafinil for the treatment of fatigue in lung cancer: a pilot study. Palliat Med. 2009; 23:325-331.
27. Jean-Pierre P, Morrow GR, Roscoe J.A., et al. A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy. Cancer. 2010; 116:3513-3520.
28. Roth AJ, Nelson C, Rosenfeld B., et al. Methylphenidate for fatigue in ambulatory men with prostate cancer. Cancer. 2010; 116:5102-5110.
29. de la Cruz M, Hui D, Parsons HA, et al. Placebo and nocebo effects in randomized double-blind clinical trials of agents for the therapy for fatigue in patients with advanced cancer. Cancer. 2010; 116:766-774.
30. Yennurajalingam S, Frisbee-Hume S, Palmer J.L., et al. Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. J Clin Oncol. 2013; 31:3076-3082.
31. Moertel CG, Schutt AJ, Reitemeier R.J., et al. Corticosteroid therapy of preterminal gastrointestinal cancer. Cancer. 1974; 33:1607-1609.
32. Bruera E, Cedaro L, Carraro S., et al. Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat Rep. 1985; 69:751-754.
33. Della Cuna GR PA, Piazzi M. Effect of methylprednisolone sodium succi-nate on quality of life in preterminal cancer patients: a placebo-controlled, multicenter study. The Methylprednisolone Preterminal Cancer Study Group. Eur J Cancer Clin Oncol. 1989; 25:1817-1821.
34. Bruera E, Hagen N, Spachynski K., et al. Effectiveness of megestrol acetate in patients with advanced cancer: a randomized, double-blind, crossover study. Cancer Prev Control. 1998; 2:74-78.
35. Bohlius J, Tonia T, Nuesch E., et al. Effects of erythropoiesis-stimulating agents on fatigue- and anaemia-related symptoms in cancer patients: systematic review and meta-analyses of published and unpublished data. Br J Cancer. 2014; 111:33-45.
36. Kelada O, Marignol L. Erythropoietin-stimulating agents and clinical outcomes in metastatic breast cancer patients with chemotherapy-induced anemia: a closed debate? Tumor Biology. 2014; 35:5095-5100.
37. Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA. 2008; 299:914-924.
38. Barton DL, Liu H, Dakhil S.R., et al. Wisconsin ginseng (Panax quinquefolius) to improve cancer-related fatigue: a randomized, doubleblind trial, N07C2. J Natl Cancer Inst. 2013; 105:1230-1238.
39. Bower JE, Bak K, Berger A., et al. Screening, assessment, and management of fatigue in adult survivors of cancer: an American Society of Clinical Oncology Clinical Practice Guideline adaptation. J Clin Oncol. 2014; 32:1840-1850.
40. de Oliveira Campos MP, Martins LC, Hassan B.J., et al. Guarana (Paullinia cupana) improves fatigue in breast cancer patients undergoing systemic chemotherapy. J Altern Complement Med. 2011; 17:505-512.
41. Ruddy KJ, Barton D, Loprinzi CL. Laying to rest psychostimulants for cancer-related fatigue? J Clin Oncol. 2014; 32:1865-1867.
42. Auret KA, Schug SA, Bremner A.P., et al. A randomized, double-blind, placebo-controlled trial assessing the impact of dexamphetamine on fatigue in patients with advanced cancer. J Pain Symptom Manage. 2009; 37:613-621.
43. Butler JM Jr, Case LD, Atkins J, et al. A phase III, double-blind, placebo-controlled prospective randomized clinical trial of D-threo-methylphenidate HCl in brain tumor patients receiving radiation therapy. Int J Radiat Oncol Biol Phys. 2007; 69:1496-1501.
44. del Fabbro E, Garcia JM, Dev R, et al. Testosterone replacement for fatigue in hypogonadal ambulatory males with advanced cancer: a preliminary double-blind placebo-controlled trial. Supportive Care in Cancer. 2013; 21:2599-2607.
45. Cruciani RA, Zhang JJ, Manola J, et al. L-Carnitine supplementation for the management of fatigue in patients with cancer: an Eastern Cooperative Oncology Group phase III, randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2012; 30:3864-3869.
46. Bruera E, El Osta B, Valero V, et al. Donepezil for cancer fatigue: a double-blind, randomized, placebo-controlled trial. J Clin Oncol. 2007; 25:3475-3481.
47. Morrow GR, Hickok JT, Roscoe J.A., et al. Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program. J Clin Oncol. 2003; 21:4635-4641.